menu
    • menu
    [{"orgOrder":0,"company":"Aethlon Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aethlon Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aethlon Medical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aethlon Medical \/ Inapplicable"},{"orgOrder":0,"company":"Varian","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Varian","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Varian \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Varian \/ Inapplicable"},{"orgOrder":0,"company":"Monteris Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Radiation","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Monteris Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monteris Medical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Monteris Medical \/ Inapplicable"},{"orgOrder":0,"company":"Neolys","sponsor":"Centre Fran\u00e7ois Baclesse | Centre Hospitalier Universitaire de Caen | Institut de canc\u00e9rologie Strasbourg Europe | Centre Oscar Lambret","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Neolys","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neolys \/ Centre Fran\u00e7ois Baclesse | Centre Hospitalier Universitaire de Caen | Institut de canc\u00e9rologie Strasbourg Europe | Centre Oscar Lambret","highestDevelopmentStatusID":"1","companyTruncated":"Neolys \/ Centre Fran\u00e7ois Baclesse | Centre Hospitalier Universitaire de Caen | Institut de canc\u00e9rologie Strasbourg Europe | Centre Oscar Lambret"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Induced Pluripotent Stem Cell Derived Natural Killer Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nuwacell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"TVAX Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TVI-Brain 1","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"TVAX Biomedical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TVAX Biomedical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TVAX Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"UWELL Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NKG2D CAR T-Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"UWELL Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UWELL Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"UWELL Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ BriaCell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ BriaCell Therapeutics"},{"orgOrder":0,"company":"Newish Technology Beijing","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NWRD09","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Newish Technology Beijing","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Newish Technology Beijing \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Newish Technology Beijing \/ Inapplicable"},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Emerson Urology Associates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Mycobacterium Bovis Bacille Calmette-Guerin Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ludwig Enterprises \/ Emerson Urology Associates","highestDevelopmentStatusID":"1","companyTruncated":"Ludwig Enterprises \/ Emerson Urology Associates"},{"orgOrder":0,"company":"Sybleu","sponsor":"Oncology Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Erlotinib","moa":"||Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sybleu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sybleu \/ Oncology Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Sybleu \/ Oncology Pharma"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adagene Suzhou Limited \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Adagene Suzhou Limited \/ National Institutes of Health"},{"orgOrder":0,"company":"GeneCentric Therapeutics","sponsor":"Atrium Health Levine Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"GeneCentric Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneCentric Therapeutics \/ Atrium Health Levine Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"GeneCentric Therapeutics \/ Atrium Health Levine Cancer Institute"},{"orgOrder":0,"company":"Neuvogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Neuvogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuvogen \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Neuvogen \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Oncolytic Polio-Rhinovirus Recombinant","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Istari Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Istari Oncology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Istari Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Salvectors Biotechnology LTD.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"YB1-X7","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Salvectors Biotechnology LTD.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Salvectors Biotechnology LTD. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Salvectors Biotechnology LTD. \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Yunpeng Liu","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Adebrelimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yunpeng Liu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yunpeng Liu \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Yunpeng Liu \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Jiangsu Healthy Life Innovation Medical Technology","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Jiangsu Healthy Life Innovation Medical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Healthy Life Innovation Medical Technology \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Jiangsu Healthy Life Innovation Medical Technology \/ AstraZeneca"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Retifanlimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Undisclosed","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Janchor Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series C Financing","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Everest Medicines","amount2":0.31,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Janchor Partners","highestDevelopmentStatusID":"1","companyTruncated":"Everest Medicines \/ Janchor Partners"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Kitov Pharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cilta-Cel","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Undisclosed","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Pudong Hospital","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Pudong Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Pudong Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Pudong Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"BW Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2020","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Undisclosed","graph3":"BW Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BW Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BW Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"923rd Hospital of Joint Logistics Support Force of PLA","sponsor":"Guangzhou Bio-gene Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"923rd Hospital of Joint Logistics Support Force of PLA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"923rd Hospital of Joint Logistics Support Force of PLA \/ Guangzhou Bio-gene Technology","highestDevelopmentStatusID":"1","companyTruncated":"923rd Hospital of Joint Logistics Support Force of PLA \/ Guangzhou Bio-gene Technology"},{"orgOrder":0,"company":"CSPC Baike","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"CSPC Baike","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSPC Baike \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CSPC Baike \/ Inapplicable"},{"orgOrder":0,"company":"Peking University","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Epirubicin Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Peking University \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Columbia University","sponsor":"Varian Medical Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mitomycin","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Varian Medical Systems","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Varian Medical Systems"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Pleco Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PTX-252","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Pleco Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hyloris Pharmaceuticals \/ Pleco Therapeutics"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"UMC Utrecht | Catharina Hospital Eindhoven | Institute Verbeeten | Elisabeth-TweeSteden Ziekenhuis | Leiden University Medical Center | Radiotherapeutic Institute Friesland | Frisius Medisch Centrum | Radiotherapy Group Deventer | Deventer Ziekenhuis | Ri","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bintrafusp Alfa","moa":"Transforming growth factor beta | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ UMC Utrecht | Catharina Hospital Eindhoven | Institute Verbeeten | Elisabeth-TweeSteden Ziekenhuis | Leiden University Medical Center | Radiotherapeutic Institute Friesland | Frisius Medisch Centrum | Radiotherapy Group Deventer | Deventer Ziekenhuis | Ri","highestDevelopmentStatusID":"1","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ UMC Utrecht | Catharina Hospital Eindhoven | Institute Verbeeten | Elisabeth-TweeSteden Ziekenhuis | Leiden University Medical Center | Radiotherapeutic Institute Friesland | Frisius Medisch Centrum | Radiotherapy Group Deventer | Deventer Ziekenhuis | Ri"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cue Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Cue Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Cue Biopharma"},{"orgOrder":0,"company":"Lantheus Medical Imaging","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu PNT2002","moa":"Beta-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lantheus Medical Imaging","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantheus Medical Imaging \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Lantheus Medical Imaging \/ Eli Lilly"},{"orgOrder":0,"company":"Procaps Group","sponsor":"BDR Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Procaps Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Procaps Group \/ BDR Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Procaps Group \/ BDR Pharmaceuticals"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Avistone Pharmaceuticals","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avistone Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Avistone Pharmaceuticals \/ Vivo Capital","highestDevelopmentStatusID":"1","companyTruncated":"Avistone Pharmaceuticals \/ Vivo Capital"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Foundation Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Foundation Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"The Department of Health, Abu Dhabi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ The Department of Health, Abu Dhabi","highestDevelopmentStatusID":"1","companyTruncated":"Merck Group \/ The Department of Health, Abu Dhabi"},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Strand Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Strand Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Strand Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"The First Affiliated Hospital of Zhengzhou University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PersonGen BioTherapeutics \/ The First Affiliated Hospital of Zhengzhou University","highestDevelopmentStatusID":"1","companyTruncated":"PersonGen BioTherapeutics \/ The First Affiliated Hospital of Zhengzhou University"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"The First Affiliated Hospital of Zhengzhou University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PD1-BCMA CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioray Laboratories \/ The First Affiliated Hospital of Zhengzhou University","highestDevelopmentStatusID":"1","companyTruncated":"Bioray Laboratories \/ The First Affiliated Hospital of Zhengzhou University"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Cangzhou People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hebei Senlang Biotechnology \/ Cangzhou People's Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Cangzhou People's Hospital"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LCAR-M61S Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ Legend Biotech","highestDevelopmentStatusID":"1","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ Legend Biotech"},{"orgOrder":0,"company":"BioSyngen","sponsor":"South China Hospital of Shenzhen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BST08","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioSyngen \/ South China Hospital of Shenzhen University","highestDevelopmentStatusID":"1","companyTruncated":"BioSyngen \/ South China Hospital of Shenzhen University"},{"orgOrder":0,"company":"Shenzhen Genocury Biotech Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JY231","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shenzhen Genocury Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen Genocury Biotech Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Genocury Biotech Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Ligachem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Ligachem Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ Ligachem Biosciences"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0.40999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ Pfizer Inc"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Foralumab","moa":"||T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Xbrane Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Xbrane Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CNBX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CNBX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AIkido Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"AIkido Pharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIkido Pharm \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AIkido Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Guangdong Provincial Hospital of Traditional Chinese Medicine","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Undisclosed","graph3":"Guangdong Provincial Hospital of Traditional Chinese Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Guangdong Provincial Hospital of Traditional Chinese Medicine \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Guangdong Provincial Hospital of Traditional Chinese Medicine \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Undisclosed","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"The National Comprehensive Cancer Network","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Decitabine","moa":"||DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Undisclosed","graph3":"The National Comprehensive Cancer Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The National Comprehensive Cancer Network \/ Taiho Oncology","highestDevelopmentStatusID":"1","companyTruncated":"The National Comprehensive Cancer Network \/ Taiho Oncology"},{"orgOrder":0,"company":"Universidade Federal do Rio de Janeiro","sponsor":"Institutos Madrile\u00f1o de Estudios Avanzados | Oncocl\u00ednicas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Oncology","graph2":"Undisclosed","graph3":"Universidade Federal do Rio de Janeiro","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universidade Federal do Rio de Janeiro \/ Institutos Madrile\u00f1o de Estudios Avanzados | Oncocl\u00ednicas","highestDevelopmentStatusID":"1","companyTruncated":"Universidade Federal do Rio de Janeiro \/ Institutos Madrile\u00f1o de Estudios Avanzados | Oncocl\u00ednicas"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Kate Farms Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Kate Farms Inc","highestDevelopmentStatusID":"1","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Kate Farms Inc"},{"orgOrder":0,"company":"Centre Fran\u00e7ois Baclesse","sponsor":"Natsuca Laboratory | Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Qiseng","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Centre Fran\u00e7ois Baclesse","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre Fran\u00e7ois Baclesse \/ Natsuca Laboratory | Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation","highestDevelopmentStatusID":"1","companyTruncated":"Centre Fran\u00e7ois Baclesse \/ Natsuca Laboratory | Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation"},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Lasofoxifene","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sermonix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sermonix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sermonix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matrix Biomed \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Matrix Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nilotinib","moa":"Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Undisclosed","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cerdulatinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase SYK | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Second Affiliated Hospital, Nanchang University","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Aumolertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Second Affiliated Hospital, Nanchang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Nanchang University \/ Hansoh Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Second Affiliated Hospital, Nanchang University \/ Hansoh Pharma"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SpringWorks Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"SpringWorks Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aveta Biomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APG-157","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aveta Biomics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aveta Biomics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aveta Biomics \/ Inapplicable"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Undisclosed","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ AstraZeneca"},{"orgOrder":0,"company":"National Institute of Cancerolog\u00eda","sponsor":"Sabinsa","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Institute of Cancerolog\u00eda","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute of Cancerolog\u00eda \/ Sabinsa","highestDevelopmentStatusID":"1","companyTruncated":"National Institute of Cancerolog\u00eda \/ Sabinsa"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zidesamtinib","moa":"ROS1 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Megestrol Acetate","moa":"Progesterone receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Taletrectinib","moa":"Proto-oncogene tyrosine-protein kinase ROS | Neurotrophic tyrosine kinase receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nuvation Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nuvation Bio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nuvation Bio \/ Inapplicable"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Synmosa","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Oxybutynin Hydrochloride","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"National Taiwan University Hospital \/ Synmosa","highestDevelopmentStatusID":"1","companyTruncated":"National Taiwan University Hospital \/ Synmosa"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"||Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellenkos","amount2":0.31,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"Tablet","sponsorNew":"Cellenkos \/ Incyte Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Cellenkos \/ Incyte Corporation"},{"orgOrder":0,"company":"The National Comprehensive Cancer Network","sponsor":"Puma Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Neratinib","moa":"Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Undisclosed","graph3":"The National Comprehensive Cancer Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The National Comprehensive Cancer Network \/ Puma Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"The National Comprehensive Cancer Network \/ Puma Biotechnology"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Comprehensive Cancer Network","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ National Comprehensive Cancer Network","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ National Comprehensive Cancer Network"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Olema Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Palazestrant","moa":"||NR3A1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Olema Oncology","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Olema Oncology"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Pacific Pediatric Neuro-Oncology Consortium","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Dordaviprone","moa":"||DRD2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pacific Pediatric Neuro-Oncology Consortium","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacific Pediatric Neuro-Oncology Consortium \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pacific Pediatric Neuro-Oncology Consortium \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Wigen Biomedicine Technology","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"WJ1075","moa":"XPO1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wigen Biomedicine Technology","amount2":0.070000000000000007,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Wigen Biomedicine Technology \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Wigen Biomedicine Technology \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Eurostars","highestDevelopmentStatusID":"1","companyTruncated":"Oryzon Genomics \/ Eurostars"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Linnaeus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"LNS8801","moa":"||GPER","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Linnaeus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Linnaeus Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Ideaya Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Darovasertib","moa":"||PKC","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Ideaya Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Korean Cancer Study Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"GEN-001","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Korean Cancer Study Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korean Cancer Study Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Korean Cancer Study Group \/ Inapplicable"},{"orgOrder":0,"company":"Oligon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Oligon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oligon \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Oligon \/ Inapplicable"},{"orgOrder":0,"company":"Labor Dr. Merk & Kollegen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Labor Dr. Merk & Kollegen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Labor Dr. Merk & Kollegen \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Labor Dr. Merk & Kollegen \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Alessa Therapeutics","sponsor":"Celanese","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alessa Therapeutics \/ Celanese","highestDevelopmentStatusID":"1","companyTruncated":"Alessa Therapeutics \/ Celanese"},{"orgOrder":0,"company":"Sanofi","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sanofi","amount2":1.54,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":1.54,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Cellevolve","sponsor":"Acclaimed Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellevolve","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cellevolve \/ Acclaimed Investors","highestDevelopmentStatusID":"1","companyTruncated":"Cellevolve \/ Acclaimed Investors"},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Five Prime Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Five Prime Therapeutics \/ Seagen","highestDevelopmentStatusID":"1","companyTruncated":"Five Prime Therapeutics \/ Seagen"},{"orgOrder":0,"company":"Myst Therapeutics","sponsor":"Turnstone Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Myst Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myst Therapeutics \/ Turnstone Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Myst Therapeutics \/ Turnstone Biologics"},{"orgOrder":0,"company":"Nusano","sponsor":"PharmaLogic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nusano","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nusano \/ PharmaLogic","highestDevelopmentStatusID":"1","companyTruncated":"Nusano \/ PharmaLogic"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Orca Bio \/ Lyell Immunopharma"},{"orgOrder":0,"company":"ScalmiBio","sponsor":"ALX Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ScalmiBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ScalmiBio \/ ALX Oncology","highestDevelopmentStatusID":"1","companyTruncated":"ScalmiBio \/ ALX Oncology"},{"orgOrder":0,"company":"Tanabe Research Laboratories","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tanabe Research Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tanabe Research Laboratories \/ Adagene Suzhou Limited","highestDevelopmentStatusID":"1","companyTruncated":"Tanabe Research Laboratories \/ Adagene Suzhou Limited"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Alta Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tyra Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Alta Partners","highestDevelopmentStatusID":"1","companyTruncated":"Tyra Biosciences \/ Alta Partners"},{"orgOrder":0,"company":"University of California","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of California \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"XOMA","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XOMA \/ Zydus Lifesciences","highestDevelopmentStatusID":"1","companyTruncated":"XOMA \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Nuntius Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nuntius Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuntius Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Nuntius Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Vycellix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Vycellix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vycellix \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vycellix \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xeris Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Xeris Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Ghent University","sponsor":"eTheRNA immunotherapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ghent University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ghent University \/ eTheRNA immunotherapies","highestDevelopmentStatusID":"1","companyTruncated":"Ghent University \/ eTheRNA immunotherapies"},{"orgOrder":0,"company":"University of Montreal","sponsor":"Medigene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Montreal","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Montreal \/ Medigene","highestDevelopmentStatusID":"1","companyTruncated":"University of Montreal \/ Medigene"},{"orgOrder":0,"company":"AllianThera Biopharma","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"AllianThera Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AllianThera Biopharma \/ Insilico Medicine","highestDevelopmentStatusID":"1","companyTruncated":"AllianThera Biopharma \/ Insilico Medicine"},{"orgOrder":0,"company":"Antengene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ WuXi Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Antengene \/ WuXi Biologics"},{"orgOrder":0,"company":"Chengdu Baiyu Pharmaceutical","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Chengdu Baiyu Pharmaceutical","amount2":1.1699999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":1.1699999999999999,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Baiyu Pharmaceutical \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Chengdu Baiyu Pharmaceutical \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"I-Mab Biopharma","amount2":0.41999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Hillhouse Capital Group","highestDevelopmentStatusID":"1","companyTruncated":"I-Mab Biopharma \/ Hillhouse Capital Group"},{"orgOrder":0,"company":"National Tsing Hua University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Tsing Hua University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Tsing Hua University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"National Tsing Hua University \/ Inapplicable"},{"orgOrder":0,"company":"Yimiao Shenzhou","sponsor":"EdiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yimiao Shenzhou","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yimiao Shenzhou \/ EdiGene","highestDevelopmentStatusID":"1","companyTruncated":"Yimiao Shenzhou \/ EdiGene"},{"orgOrder":0,"company":"Adcendo","sponsor":"Novo Seeds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adcendo","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Adcendo \/ Novo Seeds","highestDevelopmentStatusID":"1","companyTruncated":"Adcendo \/ Novo Seeds"},{"orgOrder":0,"company":"Rappta Therapeutics","sponsor":"Novo Seeds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Rappta Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Rappta Therapeutics \/ Novo Seeds","highestDevelopmentStatusID":"1","companyTruncated":"Rappta Therapeutics \/ Novo Seeds"},{"orgOrder":0,"company":"Edith Wolfson Medical Center","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Edith Wolfson Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edith Wolfson Medical Center \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Edith Wolfson Medical Center \/ Orgenesis"},{"orgOrder":0,"company":"Toshiba Corporation","sponsor":"Shinshu University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Toshiba Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toshiba Corporation \/ Shinshu University","highestDevelopmentStatusID":"1","companyTruncated":"Toshiba Corporation \/ Shinshu University"},{"orgOrder":0,"company":"ProteoNic","sponsor":"Immunomedics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProteoNic \/ Immunomedics","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic \/ Immunomedics"},{"orgOrder":0,"company":"Educell","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SLOVENIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Educell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Educell \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Educell \/ Orgenesis"},{"orgOrder":0,"company":"Affyxell Therapeutics","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Affyxell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affyxell Therapeutics \/ GenScript ProBio","highestDevelopmentStatusID":"1","companyTruncated":"Affyxell Therapeutics \/ GenScript ProBio"},{"orgOrder":0,"company":"IntoCell","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"IntoCell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IntoCell \/ Cellectar","highestDevelopmentStatusID":"1","companyTruncated":"IntoCell \/ Cellectar"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"DynamiCure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ DynamiCure","highestDevelopmentStatusID":"1","companyTruncated":"OliX Pharmaceutical \/ DynamiCure"},{"orgOrder":0,"company":"VIVEbiotech","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"VIVEbiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIVEbiotech \/ Xyphos Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"VIVEbiotech \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Lonza Group","sponsor":"CellPoint","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ CellPoint","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Group \/ CellPoint"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Autolus Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Autolus Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Autolus Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Gaeta Therapeutics","sponsor":"Oncorus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gaeta Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Gaeta Therapeutics \/ Oncorus","highestDevelopmentStatusID":"1","companyTruncated":"Gaeta Therapeutics \/ Oncorus"},{"orgOrder":0,"company":"Microbiotica","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Microbiotica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbiotica \/ Cancer Research","highestDevelopmentStatusID":"1","companyTruncated":"Microbiotica \/ Cancer Research"},{"orgOrder":0,"company":"ONI","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ONI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ONI \/ University of Pennsylvania","highestDevelopmentStatusID":"1","companyTruncated":"ONI \/ University of Pennsylvania"},{"orgOrder":0,"company":"Thor Medical","sponsor":"Nordic Nanovector","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Thor Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thor Medical \/ Nordic Nanovector","highestDevelopmentStatusID":"1","companyTruncated":"Thor Medical \/ Nordic Nanovector"},{"orgOrder":0,"company":"Tillomed Laboratories Ltd","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tillomed Laboratories Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tillomed Laboratories Ltd \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Tillomed Laboratories Ltd \/ Zentiva"},{"orgOrder":0,"company":"University of Goettingen","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Goettingen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Goettingen \/ Iksuda Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of Goettingen \/ Iksuda Therapeutics"},{"orgOrder":0,"company":"Ipca Laboratories","sponsor":"Omexa Formulary","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ipca Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipca Laboratories \/ Omexa Formulary","highestDevelopmentStatusID":"1","companyTruncated":"Ipca Laboratories \/ Omexa Formulary"},{"orgOrder":0,"company":"Clasp Therapeutics","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Clasp Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Clasp Therapeutics \/ Catalio Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"Clasp Therapeutics \/ Catalio Capital Management"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Be Biopharma","amount2":0.13,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Be Biopharma \/ Arch Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Be Biopharma \/ Arch Ventures"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Longwood Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Be Biopharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Be Biopharma \/ Longwood Fund","highestDevelopmentStatusID":"1","companyTruncated":"Be Biopharma \/ Longwood Fund"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dewpoint Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Dewpoint Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dewpoint Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"hC Bioscience","sponsor":"Taiho Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"hC Bioscience","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"hC Bioscience \/ Taiho Ventures","highestDevelopmentStatusID":"1","companyTruncated":"hC Bioscience \/ Taiho Ventures"},{"orgOrder":0,"company":"Landmark Bio","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Landmark Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Landmark Bio \/ Galapagos","highestDevelopmentStatusID":"1","companyTruncated":"Landmark Bio \/ Galapagos"},{"orgOrder":0,"company":"NextPoint","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"NextPoint","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"NextPoint \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"NextPoint \/ Leaps by Bayer"},{"orgOrder":0,"company":"ForDoz","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ForDoz","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ForDoz \/ Lupin Ltd","highestDevelopmentStatusID":"1","companyTruncated":"ForDoz \/ Lupin Ltd"},{"orgOrder":0,"company":"AIkido Pharma","sponsor":"Cedars-Sinai Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"AIkido Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIkido Pharma \/ Cedars-Sinai Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"AIkido Pharma \/ Cedars-Sinai Medical Center"},{"orgOrder":0,"company":"Athenex","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athenex \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"1","companyTruncated":"Athenex \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aviko Radiopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radiopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Leo Cancer Care","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aviko Radiopharmaceuticals \/ Leo Cancer Care","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radiopharmaceuticals \/ Leo Cancer Care"},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Neutron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aviko Radiopharmaceuticals \/ Neutron Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radiopharmaceuticals \/ Neutron Therapeutics"},{"orgOrder":0,"company":"Immunai","sponsor":"Viola Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunai","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Immunai \/ Viola Group","highestDevelopmentStatusID":"1","companyTruncated":"Immunai \/ Viola Group"},{"orgOrder":0,"company":"Nucleus RadioPharma","sponsor":"Eclipse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nucleus RadioPharma","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Nucleus RadioPharma \/ Eclipse","highestDevelopmentStatusID":"1","companyTruncated":"Nucleus RadioPharma \/ Eclipse"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Carisma Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Carisma Therapeutics"},{"orgOrder":0,"company":"Asymchem Laboratories","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Asymchem Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asymchem Laboratories \/ LaNova Medicines","highestDevelopmentStatusID":"1","companyTruncated":"Asymchem Laboratories \/ LaNova Medicines"},{"orgOrder":0,"company":"Aldevron","sponsor":"Alaunos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aldevron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldevron \/ Alaunos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Aldevron \/ Alaunos Therapeutics"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aro Biotherapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Aro Biotherapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"CuradhMTR","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"CuradhMTR","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuradhMTR \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"1","companyTruncated":"CuradhMTR \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Diverse Biotech","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Diverse Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diverse Biotech \/ Enveric Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Diverse Biotech \/ Enveric Biosciences"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Rimiducid","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"EXUMA Biotechnology","sponsor":"MSD Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"EXUMA Biotechnology","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"EXUMA Biotechnology \/ MSD Partners","highestDevelopmentStatusID":"1","companyTruncated":"EXUMA Biotechnology \/ MSD Partners"},{"orgOrder":0,"company":"Leidos","sponsor":"Targovax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Leidos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leidos \/ Targovax","highestDevelopmentStatusID":"1","companyTruncated":"Leidos \/ Targovax"},{"orgOrder":0,"company":"Seagen","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seagen \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Seagen \/ Sanofi"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"RoosterBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ RoosterBio","highestDevelopmentStatusID":"1","companyTruncated":"Senti Biosciences \/ RoosterBio"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research \/ Ideaya Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Cancer Research \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Cyprumed","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cyprumed","amount2":0.48999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.48999999999999999,"dosageForm":"Tablet","sponsorNew":"Cyprumed \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Cyprumed \/ Merck & Co"},{"orgOrder":0,"company":"Alvotech","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ICELAND","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Alvotech \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ICELAND","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alvotech \/ Fuji Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Alvotech \/ Fuji Pharma"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Mabxience","highestDevelopmentStatusID":"1","companyTruncated":"Teva Pharmaceutical Industries \/ Mabxience"},{"orgOrder":0,"company":"Mabxience","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabxience \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience \/ Abbott Laboratories"},{"orgOrder":0,"company":"Mabxience","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabxience \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Riboscience","sponsor":"Dr. Bertrand Tuan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RBS2418","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Riboscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Riboscience \/ Dr. Bertrand Tuan","highestDevelopmentStatusID":"1","companyTruncated":"Riboscience \/ Dr. Bertrand Tuan"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TAK-113","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Chest Hospital","sponsor":"Shanghai Allist Pharmaceuticals Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TKI","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Chest Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Chest Hospital \/ Shanghai Allist Pharmaceuticals Co.,Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Chest Hospital \/ Shanghai Allist Pharmaceuticals Co.,Ltd."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Genmab","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ Genmab"},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital of Soochow University \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"1","companyTruncated":"The First Affiliated Hospital of Soochow University \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Guangdong Provincial People's Hospital","sponsor":"Shenzhen Chipscreen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Guangdong Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guangdong Provincial People's Hospital \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Guangdong Provincial People's Hospital \/ Shenzhen Chipscreen Biosciences"},{"orgOrder":0,"company":"Johns Hopkins University School of Medicine","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ivospemin","moa":"Polyamine metabolic","graph1":"Oncology","graph2":"Undisclosed","graph3":"Johns Hopkins University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University School of Medicine \/ Panbela Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Johns Hopkins University School of Medicine \/ Panbela Therapeutics"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"University of Bern | Debiopharm | Werner und Hedy Berger-Janser - Stiftung","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ University of Bern | Debiopharm | Werner und Hedy Berger-Janser - Stiftung","highestDevelopmentStatusID":"1","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ University of Bern | Debiopharm | Werner und Hedy Berger-Janser - Stiftung"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CM336","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Keymed Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Keymed Biosciences"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Tedopi","moa":"||CTLs","graph1":"Oncology","graph2":"Undisclosed","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OSE Immunotherapeutics SA \/ European Investment Bank","highestDevelopmentStatusID":"1","companyTruncated":"OSE Immunotherapeutics SA \/ European Investment Bank"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Neoantigen mRNA Personalised Cancer Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stemirna Therapeutics \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"1","companyTruncated":"Stemirna Therapeutics \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Cameroon Baptist Convention Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Misoprostol","moa":"Prostanoid EP3 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Alabama at Birmingham \/ Cameroon Baptist Convention Health","highestDevelopmentStatusID":"1","companyTruncated":"University of Alabama at Birmingham \/ Cameroon Baptist Convention Health"},{"orgOrder":0,"company":"ARCAGY GINECO GROUP","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"ARCAGY GINECO GROUP","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARCAGY GINECO GROUP \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"ARCAGY GINECO GROUP \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of Ulm","sponsor":"X-act Cologne Clinical Research GmbH | Center for Clinical Studies Ulm | Merck & Co | Celltrion","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Ulm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Ulm \/ X-act Cologne Clinical Research GmbH | Center for Clinical Studies Ulm | Merck & Co | Celltrion","highestDevelopmentStatusID":"1","companyTruncated":"University of Ulm \/ X-act Cologne Clinical Research GmbH | Center for Clinical Studies Ulm | Merck & Co | Celltrion"},{"orgOrder":0,"company":"Qilu Hospital of Shandong University","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Qilu Hospital of Shandong University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Hospital of Shandong University \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Qilu Hospital of Shandong University \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TJ004309","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Undisclosed","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"131-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Y-mAbs Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Y-mAbs Therapeutics"},{"orgOrder":0,"company":"EQRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sugemalimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EQRx \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"EQRx \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"REGN5458","moa":"B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Qilu Hospital of Shandong University","sponsor":"RemeGen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Disitamab Vedotin","moa":"ERBB2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Qilu Hospital of Shandong University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Hospital of Shandong University \/ RemeGen","highestDevelopmentStatusID":"1","companyTruncated":"Qilu Hospital of Shandong University \/ RemeGen"},{"orgOrder":0,"company":"Shanghai Chest Hospital","sponsor":"Shanghai Henlius Biotech | AccuTarget MediPharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Serplulimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Chest Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Chest Hospital \/ Shanghai Henlius Biotech | AccuTarget MediPharma","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Chest Hospital \/ Shanghai Henlius Biotech | AccuTarget MediPharma"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Oncology","graph2":"Undisclosed","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MD Anderson Cancer Center \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"MD Anderson Cancer Center \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Junshi Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sintilimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Wuxi Shuangliang Biotechnology","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"C-005","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wuxi Shuangliang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wuxi Shuangliang Biotechnology \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Wuxi Shuangliang Biotechnology \/ PharmAbcine"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Xuanzhu Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"KM257","moa":"HER2D4","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Taiho Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"DR-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dren Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Dren Bio \/ Taiho Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dren Bio \/ Taiho Ventures"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"STCube","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"STT-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ STCube","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ STCube"},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Minotaur Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"HSB-1940","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hillstream BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hillstream BioPharma \/ Minotaur Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hillstream BioPharma \/ Minotaur Therapeutics"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMM20324","moa":"IL-38 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Lenalidomide","moa":"||monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Undisclosed","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ Xencor","highestDevelopmentStatusID":"1","companyTruncated":"MorphoSys \/ Xencor"},{"orgOrder":0,"company":"iBio","sponsor":"Azargen Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Undisclosed","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iBio \/ Azargen Biotechnologies","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ Azargen Biotechnologies"},{"orgOrder":0,"company":"Juno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lisocabtagene Maraleucel","moa":"B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"Juno Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Juno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EdiGene","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ET-02","moa":"CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EdiGene \/ The First Affiliated Hospital of Henan University of Science and Technology","highestDevelopmentStatusID":"1","companyTruncated":"EdiGene \/ The First Affiliated Hospital of Henan University of Science and Technology"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Cheetah Cell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NKG2D CAR-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhejiang University \/ Cheetah Cell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang University \/ Cheetah Cell Therapeutics"},{"orgOrder":0,"company":"Cheetah Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NKG2D CAR-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cheetah Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cheetah Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cheetah Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Miltenyi Biomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MB-CART19.1","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Miltenyi Biomedicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biomedicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Miltenyi Biomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Cell Origin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SY001","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cell Origin Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cell Origin Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cell Origin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Orgenesis","sponsor":"Williamsburg Venture Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"ORGCAR19","moa":"CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orgenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orgenesis \/ Williamsburg Venture Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Orgenesis \/ Williamsburg Venture Holdings"},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"InnoBation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"IBC 101","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"GenScript Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenScript Biotech Corporation \/ InnoBation","highestDevelopmentStatusID":"1","companyTruncated":"GenScript Biotech Corporation \/ InnoBation"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat","moa":"||B-cell maturation protein (TNFRSF17)","graph1":"Oncology","graph2":"Undisclosed","graph3":"SpringWorks Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpringWorks Therapeutics \/ Precision BioSciences","highestDevelopmentStatusID":"1","companyTruncated":"SpringWorks Therapeutics \/ Precision BioSciences"},{"orgOrder":0,"company":"ProMab Biotechnologies","sponsor":"Caribou Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"CB-011","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProMab Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProMab Biotechnologies \/ Caribou Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"ProMab Biotechnologies \/ Caribou Biosciences"},{"orgOrder":0,"company":"ProBioGen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Glymaxx","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProBioGen \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"ProBioGen \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Yale Cancer Center","sponsor":"Alliance For Cancer Gene Therapy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"MAEGI","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yale Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale Cancer Center \/ Alliance For Cancer Gene Therapy","highestDevelopmentStatusID":"1","companyTruncated":"Yale Cancer Center \/ Alliance For Cancer Gene Therapy"},{"orgOrder":0,"company":"Avectas Limited","sponsor":"Vycellix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"VY-M","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avectas Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avectas Limited \/ Vycellix","highestDevelopmentStatusID":"1","companyTruncated":"Avectas Limited \/ Vycellix"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Exacis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"ExaNK","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eterna Therapeutics \/ Exacis Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Eterna Therapeutics \/ Exacis Biotherapeutics"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GC027","moa":"T-cell receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Reset Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Reset Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Reset Pharmaceuticals"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Univo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Univo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Can-Fite BioPharma \/ Univo Pharmaceuticals"},{"orgOrder":0,"company":"Novocure","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Novocure","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novocure \/ Zai Lab","highestDevelopmentStatusID":"1","companyTruncated":"Novocure \/ Zai Lab"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Focused Ultrasound Foundation | Synex Consulting Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Focused Ultrasound Foundation | Synex Consulting Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Focused Ultrasound Foundation | Synex Consulting Ltd"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Providence Health & Services \/ Inapplicable"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | HollandPTC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | HollandPTC","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | HollandPTC"},{"orgOrder":0,"company":"Sonire therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Suizenji","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sonire therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonire therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sonire therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"L-Nutra","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ L-Nutra","highestDevelopmentStatusID":"1","companyTruncated":"Endeavor Health \/ L-Nutra"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"GeneCast Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ruijin Hospital \/ GeneCast Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Ruijin Hospital \/ GeneCast Biotechnology"},{"orgOrder":0,"company":"Hospital General de Mexico","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hospital General de Mexico","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital General de Mexico \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"1","companyTruncated":"Hospital General de Mexico \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Gencurix, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gencurix, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gencurix, Inc. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Gencurix, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"University Hospital, Angers","sponsor":"Vitaflo International, Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Ketogenic Diet","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University Hospital, Angers","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Angers \/ Vitaflo International, Ltd","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Angers \/ Vitaflo International, Ltd"},{"orgOrder":0,"company":"Plastic Surgery Group AG by Prof. Jian Farhadi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Red Bull","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Plastic Surgery Group AG by Prof. Jian Farhadi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plastic Surgery Group AG by Prof. Jian Farhadi \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Plastic Surgery Group AG by Prof. Jian Farhadi \/ Inapplicable"},{"orgOrder":0,"company":"International Medical University","sponsor":"Kotra Pharma (M) Sdn Bhd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"International Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Medical University \/ Kotra Pharma (M) Sdn Bhd","highestDevelopmentStatusID":"1","companyTruncated":"International Medical University \/ Kotra Pharma (M) Sdn Bhd"},{"orgOrder":0,"company":"ElmediX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ElmediX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ElmediX \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ElmediX \/ Inapplicable"},{"orgOrder":0,"company":"Peking University","sponsor":"Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China | 3D Medicines Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Peking University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University \/ Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China | 3D Medicines Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Peking University \/ Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China | 3D Medicines Corporation"},{"orgOrder":0,"company":"Gustave Roussy","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gustave Roussy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Gustave Roussy \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Gustave Roussy \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Centre Fran\u00e7ois Baclesse","sponsor":"Bionext | Neolys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Centre Fran\u00e7ois Baclesse","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Fran\u00e7ois Baclesse \/ Bionext | Neolys","highestDevelopmentStatusID":"1","companyTruncated":"Centre Fran\u00e7ois Baclesse \/ Bionext | Neolys"},{"orgOrder":0,"company":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","sponsor":"Adventia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Flavoured Oral Nutritional Supplement","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Adventia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Adventia Pharma"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Fortimel","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Inapplicable"},{"orgOrder":0,"company":"Institut Paoli-Calmettes","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Institut Paoli-Calmettes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Paoli-Calmettes \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Institut Paoli-Calmettes \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Fatty acid synthase (FASN)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Fortimel","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Inapplicable"},{"orgOrder":0,"company":"Centre Jean Perrin","sponsor":"Groupement Inter-R\u00e9gional de Recherche Clinique et d'Innovation Auvergne Rh\u00f4ne-Alpes","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Centre Jean Perrin","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Jean Perrin \/ Groupement Inter-R\u00e9gional de Recherche Clinique et d'Innovation Auvergne Rh\u00f4ne-Alpes","highestDevelopmentStatusID":"1","companyTruncated":"Centre Jean Perrin \/ Groupement Inter-R\u00e9gional de Recherche Clinique et d'Innovation Auvergne Rh\u00f4ne-Alpes"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Ensure","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Abbott Laboratories"},{"orgOrder":0,"company":"Associazione Italiana per lo Studio del Pancreas","sponsor":"General and Pancreatic Surgery Unit, University of Verona | Fondazione Valsecchi | Associazione Oltre La Ricerca | Genomica srl","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Associazione Italiana per lo Studio del Pancreas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Associazione Italiana per lo Studio del Pancreas \/ General and Pancreatic Surgery Unit, University of Verona | Fondazione Valsecchi | Associazione Oltre La Ricerca | Genomica srl","highestDevelopmentStatusID":"1","companyTruncated":"Associazione Italiana per lo Studio del Pancreas \/ General and Pancreatic Surgery Unit, University of Verona | Fondazione Valsecchi | Associazione Oltre La Ricerca | Genomica srl"},{"orgOrder":0,"company":"Flavolife Srl","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Food For Special Medical Purposes","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Flavolife Srl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Flavolife Srl \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Flavolife Srl \/ Inapplicable"},{"orgOrder":0,"company":"Energenx Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Energenx Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Energenx Medical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Energenx Medical \/ Inapplicable"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Radialis Inc. | The Princess Margaret Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Radialis Inc. | The Princess Margaret Cancer Foundation","highestDevelopmentStatusID":"1","companyTruncated":"University Health Network, Toronto \/ Radialis Inc. | The Princess Margaret Cancer Foundation"},{"orgOrder":0,"company":"Catalysis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Ocoxin","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalysis \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Catalysis \/ Inapplicable"},{"orgOrder":0,"company":"L-Nutra","sponsor":"University of Tennessee Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"L-Nutra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"L-Nutra \/ University of Tennessee Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"L-Nutra \/ University of Tennessee Medical Center"},{"orgOrder":0,"company":"Anhui Provincial Hospital","sponsor":"First Affiliated Hospital of Wannan Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Anhui Provincial Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Provincial Hospital \/ First Affiliated Hospital of Wannan Medical College","highestDevelopmentStatusID":"1","companyTruncated":"Anhui Provincial Hospital \/ First Affiliated Hospital of Wannan Medical College"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Bristol Myers Squibb | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Bristol Myers Squibb | National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Gabrail Cancer Center Research \/ Bristol Myers Squibb | National Cancer Institute"},{"orgOrder":0,"company":"Centre Jean Perrin","sponsor":"Groupement Inter-R\u00e9gional de Recherche Clinique et d'Innovation Auvergne Rh\u00f4ne-Alpes","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Centre Jean Perrin","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Jean Perrin \/ Groupement Inter-R\u00e9gional de Recherche Clinique et d'Innovation Auvergne Rh\u00f4ne-Alpes","highestDevelopmentStatusID":"1","companyTruncated":"Centre Jean Perrin \/ Groupement Inter-R\u00e9gional de Recherche Clinique et d'Innovation Auvergne Rh\u00f4ne-Alpes"},{"orgOrder":0,"company":"UTC Therapeutics Inc.","sponsor":"The First Affiliated Hospital of Zhengzhou University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"UTC Therapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UTC Therapeutics Inc. \/ The First Affiliated Hospital of Zhengzhou University","highestDevelopmentStatusID":"1","companyTruncated":"UTC Therapeutics Inc. \/ The First Affiliated Hospital of Zhengzhou University"},{"orgOrder":0,"company":"Sutter Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Shengbai","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sutter Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutter Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sutter Health \/ Inapplicable"},{"orgOrder":0,"company":"Hubei Cancer Hospital","sponsor":"Yichang Central People\u2019s Hospital | Akeso","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hubei Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hubei Cancer Hospital \/ Yichang Central People\u2019s Hospital | Akeso","highestDevelopmentStatusID":"1","companyTruncated":"Hubei Cancer Hospital \/ Yichang Central People\u2019s Hospital | Akeso"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Supportan Drink Flavour Tropical Fruit","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Peking University Cancer Hospital & Institute","sponsor":"Tianjin Chest Hospital | Peking University First Hospital | The First Hospital of Jilin University | Beijing Friendship Hospital | Shanghai General Hospital | Liaoning Cancer Hospital & Institute | Geneplus-Beijing Co. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Peking University Cancer Hospital & Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University Cancer Hospital & Institute \/ Tianjin Chest Hospital | Peking University First Hospital | The First Hospital of Jilin University | Beijing Friendship Hospital | Shanghai General Hospital | Liaoning Cancer Hospital & Institute | Geneplus-Beijing Co. Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Peking University Cancer Hospital & Institute \/ Tianjin Chest Hospital | Peking University First Hospital | The First Hospital of Jilin University | Beijing Friendship Hospital | Shanghai General Hospital | Liaoning Cancer Hospital & Institute | Geneplus-Beijing Co. Ltd."},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Immunolight","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"X-Pact","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Immunolight","highestDevelopmentStatusID":"1","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Immunolight"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"RP1","moa":"GALV-GP R-protein","graph1":"Oncology","graph2":"Undisclosed","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Microorganism","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Undisclosed","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Oncolytics Biotech","highestDevelopmentStatusID":"1","companyTruncated":"F. Hoffmann-La Roche \/ Oncolytics Biotech"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Nelitolimod","moa":"TLR9","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0.26000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.26000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ TriSalus Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"Nakhia Impex","sponsor":"Mongolian National University of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronan Fragment","moa":"CD44 \/ ECM components","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nakhia Impex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nakhia Impex \/ Mongolian National University of Medical Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Nakhia Impex \/ Mongolian National University of Medical Sciences"},{"orgOrder":0,"company":"Replimune","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replimune \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Replimune \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"iCAD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Xoft Brain IORT","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"iCAD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iCAD \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"iCAD \/ Inapplicable"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Series B Financing","leadProduct":"METTL3","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Accent Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Accent Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"1","companyTruncated":"Accent Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ Bayer AG"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ Fusion Pharma","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ Fusion Pharma"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Actinium pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"BWXT Medical Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2021","type":"Agreement","leadProduct":"225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ BWXT Medical Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ BWXT Medical Ltd."},{"orgOrder":0,"company":"Nalagenetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nalagenetics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nalagenetics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nalagenetics \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"University of New Mexico Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KHK2455","moa":"Indoleamine 2,3-dioxygenase 1 (IDO1)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ University of New Mexico Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Kirin \/ University of New Mexico Cancer Center"},{"orgOrder":0,"company":"CSPC Baike","sponsor":"Hebei Medical University Fourth Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"CSPC Baike","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Baike \/ Hebei Medical University Fourth Hospital","highestDevelopmentStatusID":"1","companyTruncated":"CSPC Baike \/ Hebei Medical University Fourth Hospital"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Undisclosed","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"xCures","sponsor":"Cancer Commons","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ulixertinib","moa":"MAP kinase ERK2 | MAP kinase ERK1","graph1":"Oncology","graph2":"Undisclosed","graph3":"xCures","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"xCures \/ Cancer Commons","highestDevelopmentStatusID":"1","companyTruncated":"xCures \/ Cancer Commons"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Marizomib","moa":"20S proteasome","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lazertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuhan Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Yuhan Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Sun Yat-sen University \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Shanghai Chest Hospital","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Anlotinib Hydrochloride","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor receptor 3 | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Chest Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Chest Hospital \/ 3D Medicines Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Chest Hospital \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Recordati Rare Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Centre for Human Drug Research \/ Recordati Rare Diseases","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Human Drug Research \/ Recordati Rare Diseases"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matrix Biomed \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Matrix Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Nalagenetics","sponsor":"SJH Initiatives | Indonesia University | MRCCC Siloam Hospitals Semanggi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nalagenetics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nalagenetics \/ SJH Initiatives | Indonesia University | MRCCC Siloam Hospitals Semanggi","highestDevelopmentStatusID":"1","companyTruncated":"Nalagenetics \/ SJH Initiatives | Indonesia University | MRCCC Siloam Hospitals Semanggi"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Dizal Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sunvozertinib","moa":"EGFR Exon20ins mutant (EGFR Exon20ins)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Dizal Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Peking Union Medical College Hospital \/ Dizal Pharmaceutical"},{"orgOrder":0,"company":"Advenchen Laboratories, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Anlotinib Hydrochloride","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor receptor 3 | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Advenchen Laboratories, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advenchen Laboratories, LLC \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Advenchen Laboratories, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Varian Medical Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Varian Medical Systems","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Varian Medical Systems"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ziftomenib","moa":"MEN1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Xiangya Hospital, Central South University","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"apatinib mesylate","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xiangya Hospital, Central South University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiangya Hospital, Central South University \/ Suzhou Suncadia Biopharmaceuticals Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Xiangya Hospital, Central South University \/ Suzhou Suncadia Biopharmaceuticals Co., Ltd."},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Undisclosed","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qilu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Qilu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ferronova Pty Ltd","sponsor":"Royal Adelaide Hospital | Austin Health | Flinders Medical Centre | Peter MacCallum Cancer Centre | South Australian Health and Medical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Iron","moa":"Hemoglobin (HB)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ferronova Pty Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferronova Pty Ltd \/ Royal Adelaide Hospital | Austin Health | Flinders Medical Centre | Peter MacCallum Cancer Centre | South Australian Health and Medical Research Institute","highestDevelopmentStatusID":"1","companyTruncated":"Ferronova Pty Ltd \/ Royal Adelaide Hospital | Austin Health | Flinders Medical Centre | Peter MacCallum Cancer Centre | South Australian Health and Medical Research Institute"},{"orgOrder":0,"company":"Addis Ababa University","sponsor":"Akay Natural Ingredients Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Addis Ababa University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Addis Ababa University \/ Akay Natural Ingredients Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"Addis Ababa University \/ Akay Natural Ingredients Private Limited"},{"orgOrder":0,"company":"The First Hospital of Jilin University","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"The First Hospital of Jilin University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Hospital of Jilin University \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"The First Hospital of Jilin University \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ABBV-CLS-484","moa":"PTPN1\/PTPN2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calico Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Calico Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Kuirong Jiang","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kuirong Jiang","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kuirong Jiang \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Kuirong Jiang \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TT-00420","moa":"AURKA","graph1":"Oncology","graph2":"Undisclosed","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransThera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TransThera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"Shanghai Longfine Biotechnology Co., Ltd. | TopAlliance","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ Shanghai Longfine Biotechnology Co., Ltd. | TopAlliance","highestDevelopmentStatusID":"1","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ Shanghai Longfine Biotechnology Co., Ltd. | TopAlliance"},{"orgOrder":0,"company":"Imaging Biometrics, LLC","sponsor":"xCures","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gallium Maltolate","moa":"RNRs","graph1":"Oncology","graph2":"Undisclosed","graph3":"Imaging Biometrics, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imaging Biometrics, LLC \/ xCures","highestDevelopmentStatusID":"1","companyTruncated":"Imaging Biometrics, LLC \/ xCures"},{"orgOrder":0,"company":"Yunpeng Liu","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yunpeng Liu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yunpeng Liu \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Yunpeng Liu \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Ningbo Medical Center Lihuili Hospital","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fruquintinib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ningbo Medical Center Lihuili Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ningbo Medical Center Lihuili Hospital \/ Shanghai Shengdi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Ningbo Medical Center Lihuili Hospital \/ Shanghai Shengdi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Cancer Research Antwerp","sponsor":"Kom Op Tegen Kanker | Naslund Medical AB | Varian Medical Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cancer Research Antwerp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research Antwerp \/ Kom Op Tegen Kanker | Naslund Medical AB | Varian Medical Systems","highestDevelopmentStatusID":"1","companyTruncated":"Cancer Research Antwerp \/ Kom Op Tegen Kanker | Naslund Medical AB | Varian Medical Systems"},{"orgOrder":0,"company":"Guangdong Association of Clinical Trials","sponsor":"Nanjing Geneseeq Technology Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Guangdong Association of Clinical Trials","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangdong Association of Clinical Trials \/ Nanjing Geneseeq Technology Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Guangdong Association of Clinical Trials \/ Nanjing Geneseeq Technology Inc."},{"orgOrder":0,"company":"Peking University Cancer Hospital & Institute","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Peking University Cancer Hospital & Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University Cancer Hospital & Institute \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Peking University Cancer Hospital & Institute \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Hubei Soundny Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hubei Soundny Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hubei Soundny Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hubei Soundny Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Pharmadrug Production GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Cepharanthine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sairiyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sairiyo Therapeutics \/ Pharmadrug Production GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Sairiyo Therapeutics \/ Pharmadrug Production GmbH"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"FCN-338","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fosun Pharmaceutical","amount2":0.44,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Fosun Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Pleco Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Plecoid","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hyloris Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Hyloris Pharmaceuticals \/ Pleco Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hyloris Pharmaceuticals \/ Pleco Therapeutics"},{"orgOrder":0,"company":"Skysong Innovations","sponsor":"Sapphire Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"SBI-183","moa":"QSOX1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Skysong Innovations","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skysong Innovations \/ Sapphire Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Skysong Innovations \/ Sapphire Biotech"},{"orgOrder":0,"company":"BWX Technologies","sponsor":"TRIUMF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"n.c.a 225-Ac","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BWX Technologies \/ TRIUMF","highestDevelopmentStatusID":"1","companyTruncated":"BWX Technologies \/ TRIUMF"},{"orgOrder":0,"company":"Kinectrics","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ytterbium-176","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kinectrics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinectrics \/ Point Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Kinectrics \/ Point Biopharma"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Hutchmed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Surufatinib","moa":"||Fibroblast growth factor receptor 1 | Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Hutchison China MediTech","highestDevelopmentStatusID":"1","companyTruncated":"BeOne Medicines \/ Hutchison China MediTech"},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Menashe Bar-Eli","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"NT219","moa":"||Insulin receptor substrate 2 (IRS2)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Purple Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purple Biotech \/ Menashe Bar-Eli","highestDevelopmentStatusID":"1","companyTruncated":"Purple Biotech \/ Menashe Bar-Eli"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"AUM001","moa":"MNK receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"AUM Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"AUM Biosciences \/ SPRIM Global Investments","highestDevelopmentStatusID":"1","companyTruncated":"AUM Biosciences \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Xylonix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"010DS-Zn","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xylonix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xylonix \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Xylonix \/ Inapplicable"},{"orgOrder":0,"company":"Incheon National University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BODIPY","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Incheon National University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incheon National University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Incheon National University \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Centyrins","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aro Biotherapeutics","amount2":1.3999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":1.3999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Aro Biotherapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Aro Biotherapeutics \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Isotopia","sponsor":"CPDC Centre for Probe Development and Commercialization","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotopia \/ CPDC Centre for Probe Development and Commercialization","highestDevelopmentStatusID":"1","companyTruncated":"Isotopia \/ CPDC Centre for Probe Development and Commercialization"},{"orgOrder":0,"company":"Isotopia","sponsor":"Seibersdorf Labor GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"n.c.a. 177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Isotopia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isotopia \/ Seibersdorf Labor GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Isotopia \/ Seibersdorf Labor GmbH"},{"orgOrder":0,"company":"Igl Pharma","sponsor":"Q2Earth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Samarium Sm-153","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Igl Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Igl Pharma \/ Q2Earth","highestDevelopmentStatusID":"1","companyTruncated":"Igl Pharma \/ Q2Earth"},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ipilimumab","moa":"||BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zenith Epigenetics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenith Epigenetics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"1","companyTruncated":"Zenith Epigenetics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Oncology","graph2":"Undisclosed","graph3":"Moleculin Biotech","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Moleculin Biotech \/ WPD Pharmaceuticals"},{"orgOrder":0,"company":"Nihon Medi-Physics","sponsor":"Cyclotron","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"225-Ac PET","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nihon Medi-Physics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nihon Medi-Physics \/ Cyclotron","highestDevelopmentStatusID":"1","companyTruncated":"Nihon Medi-Physics \/ Cyclotron"},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"177-Lu","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"SHINE Technologies","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"SHINE Technologies \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"1","companyTruncated":"SHINE Technologies \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"University of New Hampshire","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"JQ-1","moa":"||BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of New Hampshire","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Hampshire \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of New Hampshire \/ Inapplicable"},{"orgOrder":0,"company":"Medolife","sponsor":"Ministry of Environment of The Dominican Republic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"Scorpion venom","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Medolife","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medolife \/ Ministry of Environment of The Dominican Republic","highestDevelopmentStatusID":"1","companyTruncated":"Medolife \/ Ministry of Environment of The Dominican Republic"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Evergreen Theragnostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"225-Ac FAP-2286","moa":"Fibroblast activation protein","graph1":"Oncology","graph2":"Undisclosed","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Evergreen Theragnostics","highestDevelopmentStatusID":"1","companyTruncated":"Clovis Oncology \/ Evergreen Theragnostics"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"HP Plant Based","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Inapplicable"},{"orgOrder":0,"company":"Jiangxi Provincial People's Hospital","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Xingbaiji","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Jiangxi Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Jiangxi Provincial People's Hospital \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Jiangxi Provincial People's Hospital \/ Inapplicable"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Microbio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ Microbio","highestDevelopmentStatusID":"1","companyTruncated":"National Taiwan University Hospital \/ Microbio"},{"orgOrder":0,"company":"Microbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MS-20","moa":"Gut microbiome","graph1":"Oncology","graph2":"Undisclosed","graph3":"Microbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Microbio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Microbio \/ Inapplicable"},{"orgOrder":0,"company":"GenMont Biotech Incorporation","sponsor":"Mackay Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Oncology","graph2":"Undisclosed","graph3":"GenMont Biotech Incorporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenMont Biotech Incorporation \/ Mackay Memorial Hospital","highestDevelopmentStatusID":"1","companyTruncated":"GenMont Biotech Incorporation \/ Mackay Memorial Hospital"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Panolos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"PB101","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Panolos","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ Panolos"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Society of Abdominal Radiology | GE Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compounds","year":"2024","type":"Inapplicable","leadProduct":"Fluorodeoxyglucose","moa":"Glucose transporters","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Society of Abdominal Radiology | GE Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Francisco \/ Society of Abdominal Radiology | GE Healthcare"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Venbio Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2020","type":"Series A Financing","leadProduct":"225-Ac Dotatate","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"RayzeBio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"RayzeBio \/ Venbio Partners","highestDevelopmentStatusID":"1","companyTruncated":"RayzeBio \/ Venbio Partners"},{"orgOrder":0,"company":"OncoBeta","sponsor":"NanoMab Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compounds","year":"2020","type":"Agreement","leadProduct":"188-Re","moa":"Beta-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"OncoBeta","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoBeta \/ NanoMab Technology","highestDevelopmentStatusID":"1","companyTruncated":"OncoBeta \/ NanoMab Technology"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"AVM0703","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVM Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AVM Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Cellogen Therapeutics","sponsor":"Natco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellogen Therapeutics \/ Natco Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Cellogen Therapeutics \/ Natco Pharma"},{"orgOrder":0,"company":"Sylvester Comprehensive Cancer Center","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sylvester Comprehensive Cancer Center","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Sylvester Comprehensive Cancer Center \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"1","companyTruncated":"Sylvester Comprehensive Cancer Center \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Columbia University","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Fortress Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Fortress Biotech"},{"orgOrder":0,"company":"The University of British Columbia","sponsor":"Brain Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"The University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of British Columbia \/ Brain Canada","highestDevelopmentStatusID":"1","companyTruncated":"The University of British Columbia \/ Brain Canada"},{"orgOrder":0,"company":"Veripalvelu","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Veripalvelu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veripalvelu \/ Orion Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Veripalvelu \/ Orion Corporation"},{"orgOrder":0,"company":"Exacis Biotherapeutics","sponsor":"Eterna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Exacis Biotherapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Exacis Biotherapeutics \/ Eterna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Exacis Biotherapeutics \/ Eterna Therapeutics"},{"orgOrder":0,"company":"Kelonia Therapeutics","sponsor":"Alta Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kelonia Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Kelonia Therapeutics \/ Alta Partners","highestDevelopmentStatusID":"1","companyTruncated":"Kelonia Therapeutics \/ Alta Partners"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Precision BioSciences \/ Servier"},{"orgOrder":0,"company":"Sarah Cannon","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sarah Cannon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarah Cannon \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sarah Cannon \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sana Biotechnology \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Sana Biotechnology \/ National Institutes of Health"},{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Lion TCR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zelluna Immunotherapy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zelluna Immunotherapy \/ Lion TCR","highestDevelopmentStatusID":"1","companyTruncated":"Zelluna Immunotherapy \/ Lion TCR"},{"orgOrder":0,"company":"Kalthera","sponsor":"ImmPACT Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kalthera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalthera \/ ImmPACT Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kalthera \/ ImmPACT Bio"},{"orgOrder":0,"company":"VyGen-Bio","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"VyGen-Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VyGen-Bio \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"VyGen-Bio \/ Coeptis Pharmaceuticals"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Department of Health - Abu Dhabi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Department of Health - Abu Dhabi","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ Department of Health - Abu Dhabi"},{"orgOrder":0,"company":"SteroTherapeutics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"SteroTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SteroTherapeutics \/ Moffitt Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"SteroTherapeutics \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Synthon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Synthon Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Synthon Pharmaceuticals"},{"orgOrder":0,"company":"Certara","sponsor":"Arvinas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Certara","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Certara \/ Arvinas","highestDevelopmentStatusID":"1","companyTruncated":"Certara \/ Arvinas"},{"orgOrder":0,"company":"Cellares","sponsor":"UW School of Medicine and Public Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellares","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellares \/ UW School of Medicine and Public Health","highestDevelopmentStatusID":"1","companyTruncated":"Cellares \/ UW School of Medicine and Public Health"},{"orgOrder":0,"company":"Concert AI","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Concert AI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concert AI \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Concert AI \/ Bayer AG"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Mitsubishi Tanabe Pharma America","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SparX Biopharmaceutical \/ Mitsubishi Tanabe Pharma America","highestDevelopmentStatusID":"1","companyTruncated":"SparX Biopharmaceutical \/ Mitsubishi Tanabe Pharma America"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Hebei Yanda Ludaopei Hospital | Beijing Lu Daopei Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CD19 CAR-T Cell","moa":"CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Hebei Yanda Ludaopei Hospital | Beijing Lu Daopei Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Hebei Yanda Ludaopei Hospital | Beijing Lu Daopei Hospital"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CD22 CAR-T Cell","moa":"CD22","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Hebei Medical University Fourth Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Hebei Medical University Fourth Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Hebei Medical University Fourth Hospital"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Hebei Medical University Fourth Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Hebei Medical University Fourth Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Hebei Medical University Fourth Hospital"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Hebei Medical University Fourth Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Hebei Medical University Fourth Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Hebei Medical University Fourth Hospital"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CD276 CAR-T Cell","moa":"CD276","graph1":"Oncology","graph2":"Undisclosed","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PersonGen BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"PersonGen BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Anhui Provincial Cancer Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"gucy2c CART Cell","moa":"GUCY2C","graph1":"Oncology","graph2":"Undisclosed","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovative Cellular Therapeutics \/ Anhui Provincial Cancer Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Innovative Cellular Therapeutics \/ Anhui Provincial Cancer Hospital"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Senl-h19 CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Kantonsspital Winterthur","sponsor":"Krebsforschung Schweiz, Bern, Switzerland | Sponser Sport Food AG | Leitwert GmbH | SNAQ AG | Kantonsspital St. Gallen CTU","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Whey Protein Supplement High in Leucine and \u0392-Hydroxy-\u0392-Methylbutyrate","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kantonsspital Winterthur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kantonsspital Winterthur \/ Krebsforschung Schweiz, Bern, Switzerland | Sponser Sport Food AG | Leitwert GmbH | SNAQ AG | Kantonsspital St. Gallen CTU","highestDevelopmentStatusID":"1","companyTruncated":"Kantonsspital Winterthur \/ Krebsforschung Schweiz, Bern, Switzerland | Sponser Sport Food AG | Leitwert GmbH | SNAQ AG | Kantonsspital St. Gallen CTU"},{"orgOrder":0,"company":"EBG MedAustron GmbH","sponsor":"Landesklinkum Wiener Neustadt","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Proton Ion","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"EBG MedAustron GmbH","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EBG MedAustron GmbH \/ Landesklinkum Wiener Neustadt","highestDevelopmentStatusID":"1","companyTruncated":"EBG MedAustron GmbH \/ Landesklinkum Wiener Neustadt"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Senl-T7","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Senl-T7","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Anhui Provincial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TAA05 cell","moa":"Tumor antigen","graph1":"Oncology","graph2":"Undisclosed","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PersonGen BioTherapeutics \/ Anhui Provincial Hospital","highestDevelopmentStatusID":"1","companyTruncated":"PersonGen BioTherapeutics \/ Anhui Provincial Hospital"},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CT0590","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital of Soochow University \/ CARsgen Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"The First Affiliated Hospital of Soochow University \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"Groupe Francais De Pneumo-Cancerologie","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Rnaseq","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Groupe Francais De Pneumo-Cancerologie","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francais De Pneumo-Cancerologie \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Groupe Francais De Pneumo-Cancerologie \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Shengjing Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR-1316","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shengjing Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shengjing Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Shengjing Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Weijia Fang, MD","sponsor":"Nanjing Blue Shield Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Mesothelin-Specific Car-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Weijia Fang, MD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Weijia Fang, MD \/ Nanjing Blue Shield Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Weijia Fang, MD \/ Nanjing Blue Shield Biotech"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"University of Manchester","sponsor":"Children's Cancer and Leukaemia Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Granulocytes","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Manchester","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manchester \/ Children's Cancer and Leukaemia Group","highestDevelopmentStatusID":"1","companyTruncated":"University of Manchester \/ Children's Cancer and Leukaemia Group"},{"orgOrder":0,"company":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","sponsor":"Instituto de Nutrici\u00f3n y Tecnolog\u00eda de los Alimentos | Medicinal Gardens S.L","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DMB","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Instituto de Nutrici\u00f3n y Tecnolog\u00eda de los Alimentos | Medicinal Gardens S.L","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ Instituto de Nutrici\u00f3n y Tecnolog\u00eda de los Alimentos | Medicinal Gardens S.L"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"Philips | Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"99m-Tc Nanocolloid","moa":"Reticuloendothelial system","graph1":"Oncology","graph2":"Undisclosed","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radboud University Medical Center \/ Philips | Johnson & Johnson","highestDevelopmentStatusID":"1","companyTruncated":"Radboud University Medical Center \/ Philips | Johnson & Johnson"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hebei Senlang Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Hebei Senlang Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Senl-T7","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Senlang Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hebei Senlang Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Senlang Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Paula and Rodger Riney Foundation | Plantable | M and M labs | VeggieDoctor | Sabinsa pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Algae Omega 3","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Paula and Rodger Riney Foundation | Plantable | M and M labs | VeggieDoctor | Sabinsa pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Paula and Rodger Riney Foundation | Plantable | M and M labs | VeggieDoctor | Sabinsa pharmaceuticals"},{"orgOrder":0,"company":"Changhai Hospital","sponsor":"Shanghai Ultra-T Immune Therapeutics Co. LTD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TM4SF1","moa":"TM4SF1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Changhai Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changhai Hospital \/ Shanghai Ultra-T Immune Therapeutics Co. LTD","highestDevelopmentStatusID":"1","companyTruncated":"Changhai Hospital \/ Shanghai Ultra-T Immune Therapeutics Co. LTD"},{"orgOrder":0,"company":"Second Affiliated Hospital, Soochow University","sponsor":"Soochow T-Maximun Biotechnology Co. LTD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IL-13 R\u03b12 UCAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Second Affiliated Hospital, Soochow University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Soochow University \/ Soochow T-Maximun Biotechnology Co. LTD","highestDevelopmentStatusID":"1","companyTruncated":"Second Affiliated Hospital, Soochow University \/ Soochow T-Maximun Biotechnology Co. LTD"},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CT0594CP","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"The First Affiliated Hospital of Soochow University \/ CARsgen Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"The First Affiliated Hospital of Soochow University \/ CARsgen Therapeutics"},{"orgOrder":0,"company":"Shantou University Medical College","sponsor":"ProCapZoom Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SZ003","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shantou University Medical College","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shantou University Medical College \/ ProCapZoom Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Shantou University Medical College \/ ProCapZoom Biosciences"},{"orgOrder":0,"company":"Jianming Xu","sponsor":"NeoCura","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XH001","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Jianming Xu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jianming Xu \/ NeoCura","highestDevelopmentStatusID":"1","companyTruncated":"Jianming Xu \/ NeoCura"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CLL1\/CD33 CAR-T Cell","moa":"CLL1\/CD33","graph1":"Oncology","graph2":"Undisclosed","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangzhou Bio-gene Technology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Guangzhou Bio-gene Technology \/ Inapplicable"},{"orgOrder":0,"company":"Institut Cancerologie de l'Ouest","sponsor":"Diagnostica Stago","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Thrombogram","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Institut Cancerologie de l'Ouest","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Cancerologie de l'Ouest \/ Diagnostica Stago","highestDevelopmentStatusID":"1","companyTruncated":"Institut Cancerologie de l'Ouest \/ Diagnostica Stago"},{"orgOrder":0,"company":"University of Arizona","sponsor":"Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Enfamil Neuropro","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Arizona \/ Mead Johnson Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"University of Arizona \/ Mead Johnson Nutrition"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCMA\/GPRC5D Double CAR-T Cell","moa":"B-cell maturation antigen\/GPRC5D","graph1":"Oncology","graph2":"Undisclosed","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangzhou Bio-gene Technology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Guangzhou Bio-gene Technology \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Tc-99m Pentetate","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ National Institutes of Health"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GT201","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GRIT Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai General Hospital","sponsor":"Shenzhen Zhongke Qiyuan Biotechnology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"QY-1-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai General Hospital \/ Shenzhen Zhongke Qiyuan Biotechnology Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai General Hospital \/ Shenzhen Zhongke Qiyuan Biotechnology Co., Ltd."},{"orgOrder":0,"company":"Poznan University of Medical Sciences","sponsor":"MagForce USA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Nanotherm Therapy","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Poznan University of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Poznan University of Medical Sciences \/ MagForce USA","highestDevelopmentStatusID":"1","companyTruncated":"Poznan University of Medical Sciences \/ MagForce USA"},{"orgOrder":0,"company":"PersonGen BioTherapeutics","sponsor":"Second Affiliated Hospital, Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"UTAA17","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"PersonGen BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PersonGen BioTherapeutics \/ Second Affiliated Hospital, Soochow University","highestDevelopmentStatusID":"1","companyTruncated":"PersonGen BioTherapeutics \/ Second Affiliated Hospital, Soochow University"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IGM2323","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Wu Wenming","sponsor":"NeoCura","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"XH001","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wu Wenming","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wu Wenming \/ NeoCura","highestDevelopmentStatusID":"1","companyTruncated":"Wu Wenming \/ NeoCura"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GT307","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GRIT Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BLa80","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GT201","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GRIT Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Zhengzhou Revo-Gene Technology Co., LTD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Tumor Polypeptide Pool","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zhengzhou Revo-Gene Technology Co., LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhengzhou Revo-Gene Technology Co., LTD \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhengzhou Revo-Gene Technology Co., LTD \/ Inapplicable"},{"orgOrder":0,"company":"GenieBiome Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BLHK03","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"GenieBiome Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenieBiome Limited \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GenieBiome Limited \/ Inapplicable"},{"orgOrder":0,"company":"RenJi Hospital","sponsor":"Acellytron Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ACT-001 CAR-NK cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"RenJi Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RenJi Hospital \/ Acellytron Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"RenJi Hospital \/ Acellytron Therapeutics"},{"orgOrder":0,"company":"Shenzhen Genocury Biotech Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JY231","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shenzhen Genocury Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen Genocury Biotech Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Genocury Biotech Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Medical University Cancer Institute and Hospital","sponsor":"Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CHT102","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tianjin Medical University Cancer Institute and Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tianjin Medical University Cancer Institute and Hospital \/ Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Medical University Cancer Institute and Hospital \/ Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"rMBCG","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Second Life Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SL-28","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Second Life Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Life Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Second Life Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Aposense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Processa Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Aposense","highestDevelopmentStatusID":"1","companyTruncated":"Processa Pharmaceuticals \/ Aposense"},{"orgOrder":0,"company":"Bionaut Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA | DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bionaut Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionaut Labs \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bionaut Labs \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Vaccinia virus Copenhagen Strain","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Undisclosed","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Indiana University | VA Cooperative Studies Program | L-Nutra","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Xentigen","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ Indiana University | VA Cooperative Studies Program | L-Nutra","highestDevelopmentStatusID":"1","companyTruncated":"VA Office of Research and Development \/ Indiana University | VA Cooperative Studies Program | L-Nutra"},{"orgOrder":0,"company":"CoImmune","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"ITI-1020","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"CoImmune","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CoImmune \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CoImmune \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SNP-7\/8a","moa":"CD8 T-cell","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avidea Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avidea Technologies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avidea Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Jianming Xu","sponsor":"NeoCura","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Jianming Xu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jianming Xu \/ NeoCura","highestDevelopmentStatusID":"1","companyTruncated":"Jianming Xu \/ NeoCura"},{"orgOrder":0,"company":"Shen Lin","sponsor":"NeoCura","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shen Lin","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shen Lin \/ NeoCura","highestDevelopmentStatusID":"1","companyTruncated":"Shen Lin \/ NeoCura"},{"orgOrder":0,"company":"YueJuan Cheng","sponsor":"NeoCura","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Personalized Neoantigen Tumor Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"YueJuan Cheng","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YueJuan Cheng \/ NeoCura","highestDevelopmentStatusID":"1","companyTruncated":"YueJuan Cheng \/ NeoCura"},{"orgOrder":0,"company":"Shanghai 10th People's Hospital","sponsor":"NeoVax Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Neoantigen Peptide Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai 10th People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai 10th People's Hospital \/ NeoVax Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai 10th People's Hospital \/ NeoVax Biotechnology"},{"orgOrder":0,"company":"The First Affiliated Hospital of Nanchang University","sponsor":"Shanghai Dengding BioAI Co.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Neoantigen Peptide Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"The First Affiliated Hospital of Nanchang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital of Nanchang University \/ Shanghai Dengding BioAI Co.","highestDevelopmentStatusID":"1","companyTruncated":"The First Affiliated Hospital of Nanchang University \/ Shanghai Dengding BioAI Co."},{"orgOrder":0,"company":"Queen's University","sponsor":"MERCK CANADA INC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Queen's University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen's University \/ MERCK CANADA INC","highestDevelopmentStatusID":"1","companyTruncated":"Queen's University \/ MERCK CANADA INC"},{"orgOrder":0,"company":"Spaarne Gasthuis","sponsor":"Canisius-Wilhelmina Hospital | Isabelle Henskens | Noordwest Ziekenhuisgroep | Alrijne Hospital | Dijklander Ziekenhuis | Ziekenhuisgroep Twente | Diakonessenhuis, Utrecht | ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Oncology","graph2":"Undisclosed","graph3":"Spaarne Gasthuis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaarne Gasthuis \/ Canisius-Wilhelmina Hospital | Isabelle Henskens | Noordwest Ziekenhuisgroep | Alrijne Hospital | Dijklander Ziekenhuis | Ziekenhuisgroep Twente | Diakonessenhuis, Utrecht | ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Spaarne Gasthuis \/ Canisius-Wilhelmina Hospital | Isabelle Henskens | Noordwest Ziekenhuisgroep | Alrijne Hospital | Dijklander Ziekenhuis | Ziekenhuisgroep Twente | Diakonessenhuis, Utrecht | ZonMw"},{"orgOrder":0,"company":"University Medical Centre Ljubljana","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"University Medical Centre Ljubljana","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Centre Ljubljana \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University Medical Centre Ljubljana \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mayo Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Cells & Genes Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CG-102-12C","moa":"GPC3","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Cells & Genes Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang University \/ Cells & Genes Biotech"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"TCR\u03b1\u03b2+\/CD45RA","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ruijin Hospital \/ Miltenyi Biotec","highestDevelopmentStatusID":"1","companyTruncated":"Ruijin Hospital \/ Miltenyi Biotec"},{"orgOrder":0,"company":"Hebei Taihe Chunyu Biotechnology","sponsor":"Qi deng","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CD7 CAR-T Cell","moa":"CD7","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hebei Taihe Chunyu Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hebei Taihe Chunyu Biotechnology \/ Qi deng","highestDevelopmentStatusID":"1","companyTruncated":"Hebei Taihe Chunyu Biotechnology \/ Qi deng"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LCAR-F33S","moa":"T lymphocyte","graph1":"Oncology","graph2":"Undisclosed","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Institute of Hematology & Blood Diseases Hospital, China","highestDevelopmentStatusID":"1","companyTruncated":"Legend Biotech \/ Institute of Hematology & Blood Diseases Hospital, China"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"UTC Therapeutics Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Anti-Mesothelin CAR-T Cell","moa":"MSLN","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhejiang University \/ UTC Therapeutics Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang University \/ UTC Therapeutics Inc."},{"orgOrder":0,"company":"Sinotau Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compounds","year":"2025","type":"Inapplicable","leadProduct":"18-F Flotufolastat","moa":"PSMA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sinotau Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinotau Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sinotau Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2025","type":"Inapplicable","leadProduct":"18-F rhPSMA-7.3","moa":"PSMA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"1","companyTruncated":"Hackensack Meridian Health \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Case Comprehensive Cancer Center","sponsor":"HistoSonics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Case Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Case Comprehensive Cancer Center \/ HistoSonics","highestDevelopmentStatusID":"1","companyTruncated":"Case Comprehensive Cancer Center \/ HistoSonics"},{"orgOrder":0,"company":"Newish Technology Beijing","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NWRD09","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Newish Technology Beijing","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Newish Technology Beijing \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Newish Technology Beijing \/ Undisclosed"}]

    Find Novel Oncology Drugs in Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-787

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access to ABBV-787

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 03, 2024

                            Lead Product(s) : ABBV-787

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telisotuzumab Adizutecan

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access to Telisotuzumab Adizutecan

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            August 09, 2023

                            Lead Product(s) : Telisotuzumab Adizutecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Department of Health - Abu Dhabi

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Department of Health - Abu Dhabi, M42 and AbbVie Enter a Strategic Partnership to Advance Personalised Medicin...

                            Details : The agreement aims to advance personalised, genomics and precision medicine in the diagnosis and treatment of multiple myeloma and non-small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 19, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Department of Health - Abu Dhabi

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AbbVie Inc

                            U.S.A
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epcoritamab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Genmab

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access to Epcoritamab

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 20, 2023

                            Lead Product(s) : Epcoritamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Genmab

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AbbVie Inc

                            U.S.A
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telisotuzumab Vedotin

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access to Telisotuzumab Vedotin

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            April 05, 2021

                            Lead Product(s) : Telisotuzumab Vedotin

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,540.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outsi...

                            Details : This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $40.0 million

                            October 01, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,540.0 million

                            Deal Type : Licensing Agreement

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : K-NK002

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kiadis Pharma Files First Investigational New Drug Application with The U.S. FDA for Natural Killer Cell Thera...

                            Details : IND supports the Company’s planned NK-REALM Phase 1/2 study which will evaluate K-NK002 in 63 patients with blood cancer undergoing a haploidentical hematopoietic stem cell transplant (HSCT).

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 04, 2020

                            Lead Product(s) : K-NK002

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Kreos

                            Deal Size : $5.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Kiadis Announces the Placement of €5 Million Convertible Bonds with Kreos

                            Details : The conversion of a sizeable portion of Kiadis's loan into a convertible structure supports its recent refocus on its proprietary K-NK platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $5.9 million

                            January 10, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Kreos

                            Deal Size : $5.9 million

                            Deal Type : Financing

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lee Pharma

                            India
                            CPhI WW Frankfurt
                            Booth #11.1C68
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of a Novel Leuprolide With Market Leuprolide

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            September 10, 2018

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AbbVie Inc

                            U.S.A
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Navitoclax

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access to Navitoclax

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 19, 2018

                            Lead Product(s) : Navitoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth